Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
Colorectal Cancer Pipeline 2024: Innovations in Treatment
Research & Development Colorectal Cancer Pipeline 2024: Innovations in Treatment

As the battle against cancer continues, one particular area showing remarkable strides is colorectal cancer research and treatment. With over 195 key players in the industry, a testament to the competitive yet collaborative nature of the field, advancements are moving at an incredible pace. From

Sunshine Biopharma's Turbulent Year: Growth to Steep Decline
Management & Regulatory Sunshine Biopharma's Turbulent Year: Growth to Steep Decline

In the dynamic landscape of the stock market, few stories encapsulate the sheer unpredictability like that of Sunshine Biopharma Inc. (SBFM). From dizzying peaks to harrowing valleys, SBFM's fiscal journey over the past year reads like a thrilling financial epic. With the highest crest at

Is CAR T-cell Therapy the Future of Cancer Treatment?
Research & Development Is CAR T-cell Therapy the Future of Cancer Treatment?

The battle against cancer is one that has engaged the global medical community for decades, and with the emergence of Chimeric Antigen Receptor (CAR) T-cell therapy, we stand on the precipice of a significant revolution in the way cancer is treated. This immunotherapy transforms a patient's

EU Debates Extending Medicinal Data Protection Window
Management & Regulatory EU Debates Extending Medicinal Data Protection Window

In the ever-evolving landscape of pharmaceuticals, the debate over regulatory data protection (RDP) is intensifying. As the Belgian Presidency of the Council of the EU approaches its twilight, policymakers are grappling with how to balance the imperatives of fostering pharmaceutical innovation with

NIBRT Opens €21M Biopharma Facility Boosting Ireland's Sector
Management & Regulatory NIBRT Opens €21M Biopharma Facility Boosting Ireland's Sector

The landscape of biopharmaceutical manufacturing in Ireland has recently welcomed an impressive addition with the inauguration of the National Institute for Bioprocessing Research and Training's (NIBRT) new facility. This state-of-the-art establishment in Dublin, conceived with a robust €21 m

Surging Lab Automation Market to Hit $11.31B by 2031
Research & Development Surging Lab Automation Market to Hit $11.31B by 2031

The lab automation market is a rapidly growing field, expected to reach a staggering $11.31 billion by 2031. This growth is driven by several factors, including increased R&D spending, the rising prevalence of chronic and infectious diseases, higher demand for lab automation, and significant

BIO Weighs Impact of Biosecurity Bill on Drug Developers
Biotech & Bioprocessing BIO Weighs Impact of Biosecurity Bill on Drug Developers

The biotechnology sector could be on the brink of a substantial change as legislative gears turn with the possibility of the BIOSECURE Act being widened to encompass drug developers. This pivot towards inclusive scrutiny, primarily targeting relationships with Chinese biopharma entities, sparks a

How Can Nanoparticles Break the Blood-Brain Barrier in Cancer Therapy?
Research & Development How Can Nanoparticles Break the Blood-Brain Barrier in Cancer Therapy?

How Can Nanoparticles Break the Blood-Brain Barrier in Cancer Therapy? The University of Miami Miller School of Medicine's Sylvester Comprehensive Cancer Center has unveiled an astonishing breakthrough in the realm of cancer nanotherapy. This cutting-edge approach could revolutionize how both

How Will Peptide Nanofibers Revolutionize Regenerative Medicine?
Biotech & Bioprocessing How Will Peptide Nanofibers Revolutionize Regenerative Medicine?

In an era characterized by breakthrough innovations in medical technology, peptide-based nanofiber hydrogels stand out as a transformative advancement in regenerative medicine. Seminal work by researchers at Rice University and the University of Houston exemplifies the innovative thinking that

How Is AI Changing the Drug Discovery Landscape?
Research & Development How Is AI Changing the Drug Discovery Landscape?

The inception of artificial intelligence (AI) into the realm of drug discovery heralds a new era for the pharmaceutical industry. The traditional drug development pipeline, usually protracted and costly, is undergoing a radical transformation. This article delves into the ways AI is reshaping this

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later